Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

ThromboGenics teams up with Eleven Biotherapeutics for back-of-the-eye disease treatment

Executive Summary

Three-year-old protein-based therapeutics developer Eleven Biotherapeutics has agreed to use its AMP-Rx protein design technology to optimize one of ThromboGenics NV’s therapeutics. The biologic will be used to treat back-of-the-eye diseases, including diabetic macular edema.
Deal Industry
  • Pharmaceuticals
  • Biotechnology
    • Large Molecule
Deal Status
  • Final
Deal Type
  • Alliance
    • Includes Contract
    • Includes Royalty or Profit Split Information
    • Intra-Biotech Deal
    • R&D and Marketing (Licensing)

Related Companies